DNA Non-coding Regions Identified as Therapeutic Targets for Prostate Cancer, New Study Suggests

DNA Non-coding Regions Identified as Therapeutic Targets for Prostate Cancer, New Study Suggests
Six regions in the non-coding parts of the DNA that surround FOXA1, a major prostate cancer driver, may be therapeutic targets for lowering the amount of this cancer-promoting protein — and potentially impairing the growth of prostate cancer cells, a new study suggests. FOXA1 is involved in a variety of other cancers, but its three-dimensional structure has largely hampered the development of effective inhibitors. The newly discovered regions may present a good alternative to modulate FOXA1 activity, the researchers said. Titled “Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer,” the study was published in Nature A protein found in many parts of the body, FOXA1 has been specifically implicated in the development of prostate cancer. Mutations in the FOXA1 gene, and the DNA sequence that surrounds the gene — which controls the levels of FOXA1 protein — are found in men with early and advanced prostate cancers. The function of FOXA1 is to bind directly to DNA, allowing genes to be read and proteins t
Subscribe or to access all post and page content.